Back

Sglt2 inhibitors vs. dpp-4 inhibitors and glp-1 receptor agonists on atrial fibrillation incidence in type 2 diabetes: a meta-analysis

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Risk factor management in atrial fibrillation patients Prevention EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mr Ihsan Fachry Arba

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Implementation gaps in modifiable risk Factor management among atrial fibrillation patients: a real-world retrospective study from a UK district general hospital
Doctor A. Abdalla (Blackpool, GB)
Abstract Slides Video
Presentation thumbnail
Impact of weight status on in-hospital outcomes in atrial fibrillation: a nationwide analysis
Doctor A. Folman (Hadera, IL)
Presentation thumbnail
Congestion and quality of life in atrial fibrillation and heart failure
Ms A. Zandijk (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Sex-based differences in bi-atrial structure, function, and electrophysiology in atrial fibrillation
Doctor N. Bodagh (London, GB)
Abstract Slides Video
Presentation thumbnail
Cardiovascular-kidney-metabolic syndrome and atrial fibrillation: insights from two real-world prospective registries across europe and east asia
Doctor M. Rossi (Liverpool, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factor management in atrial fibrillation patients

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis
thumbnail
Congress Presentation
Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved ejection fraction - A meta-analysis of randomised-controlled trials
thumbnail
Congress Presentation
A reduction in atrial fibrillation incidence in obese patients on SGLT2 Inhibitors: a scoping review

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources